![Henning Scheich](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Henning Scheich
Fondateur chez Leibniz Institute for Neurobiology
Postes actifs de Henning Scheich
Sociétés | Poste | Début | Fin |
---|---|---|---|
Leibniz Institute for Neurobiology | Fondateur | 31/08/2009 | - |
Corporate Officer/Principal | 31/08/2009 | - | |
Germany Ministry of Education & Research | Corporate Officer/Principal | 31/08/2009 | - |
Historique de carrière de Henning Scheich
Anciens postes connus de Henning Scheich
Sociétés | Poste | Début | Fin |
---|---|---|---|
KeyNeurotek Pharmaceuticals AG
![]() KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Directeur/Membre du Conseil | 31/08/2009 | 03/08/2011 |
Fondateur | 31/08/2009 | 03/08/2011 |
Statistiques
Internationale
Allemagne | 4 |
Opérationnelle
Corporate Officer/Principal | 2 |
Founder | 2 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
KeyNeurotek Pharmaceuticals AG
![]() KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
Leibniz Institute for Neurobiology | |
Germany Ministry of Education & Research | Government |
- Bourse
- Insiders
- Henning Scheich
- Expérience